Publicacións en colaboración con investigadores/as de University of Cambridge (55)

2023

  1. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

    Nature Genetics, Vol. 55, Núm. 12, pp. 2065-2074

  2. Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry

    American Journal of Human Genetics, Vol. 110, Núm. 7, pp. 1200-1206

2022

  1. Erratum: Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (European journal of human genetics : EJHG (2022) 30 3 (349-362))

    European journal of human genetics : EJHG

  2. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

    European journal of human genetics : EJHG, Vol. 30, Núm. 3, pp. 349-362

  3. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score

    Prostate cancer and prostatic diseases, Vol. 25, Núm. 4, pp. 755-761

2021

  1. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

    Nature Communications, Vol. 12, Núm. 1

  2. Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer

    Prostate Cancer and Prostatic Diseases, Vol. 24, Núm. 2, pp. 532-541

  3. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations

    Nature Communications, Vol. 12, Núm. 1

  4. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (Nature Genetics, (2021), 53, 1, (65-75), 10.1038/s41588-020-00748-0)

    Nature Genetics

  5. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

    Nature Genetics, Vol. 53, Núm. 1, pp. 65-75

2020

  1. A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort

    Frontiers in Oncology, Vol. 10

  2. An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk

    Nature Communications, Vol. 11, Núm. 1

  3. Characterization of the Cancer Spectrum in Men with Germline BRCA1 and BRCA2 Pathogenic Variants: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

    JAMA Oncology, Vol. 6, Núm. 8, pp. 1218-1230

  4. External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort

    Frontiers in Oncology, Vol. 10

  5. Genome wide association study of acute radiation toxicity and quality of life in breast cancer patients – results from the REQUITE cohort study

    European Journal of Cancer, Vol. 138, pp. S12

  6. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

    Nature Genetics, Vol. 52, Núm. 6, pp. 572-581

  7. Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan

    Nature Communications, Vol. 11, Núm. 1

  8. Ovarian and Breast Cancer Risks Associated with Pathogenic Variants in RAD51C and RAD51D

    Journal of the National Cancer Institute, Vol. 112, Núm. 12, pp. 1242-1250

  9. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

    Genetics in Medicine, Vol. 22, Núm. 10, pp. 1653-1666

  10. The CHEK2 variant C.349A>G is associated with prostate cancer risk and carriers share a common ancestor

    Cancers, Vol. 12, Núm. 11, pp. 1-17